Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS - Free Report) in a research report report published on Monday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the biopharmaceutical company's stock.

A number of other research analysts have also recently commented on the company. StockNews.com upgraded Regulus Therapeutics to a "sell" rating in a report on Tuesday, September 17th. Oppenheimer restated an "outperform" rating and set a $7.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Regulus Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $10.80.

Regulus Therapeutics Stock Performance

Shares of RGLS stock traded down $0.06 during mid-day trading on Monday, hitting $1.41. The company's stock had a trading volume of 500,735 shares, compared to its average volume of 1,265,676. The stock has a market cap of $92.31 million, a price-to-earnings ratio of -1.31 and a beta of 1.63. The business has a 50-day moving average price of $1.55 and a 200 day moving average price of $1.82. Regulus Therapeutics has a 52-week low of $1.08 and a 52-week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). Equities research analysts predict that Regulus Therapeutics will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of RGLS. NEA Management Company LLC purchased a new position in shares of Regulus Therapeutics during the 1st quarter valued at $18,627,000. RA Capital Management L.P. purchased a new position in Regulus Therapeutics during the 1st quarter valued at about $18,000,000. Vanguard Group Inc. grew its position in Regulus Therapeutics by 158.4% during the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company's stock valued at $2,132,000 after purchasing an additional 453,784 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Regulus Therapeutics by 10.4% during the 3rd quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company's stock valued at $626,000 after acquiring an additional 37,480 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Regulus Therapeutics in the 2nd quarter worth approximately $352,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.